SCHEMBL21136339

SCHEMBL21136339

CC(O)[C@@H](CO)O[C@H](CO)n1cnc2c(N(C)C)nc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.40
CDK1 P06493 5/20 0.40
CCNE1 P24864 4/20 0.40
CCNB1 P14635 2/20 0.40
PRKACA P17612 1/20 0.38
CCNA2 P20248 1/20 0.38
PRKACG P22612 1/20 0.38
PRKACB P22694 1/20 0.38
MAPK3 P27361 1/20 0.38
MAPK1 P28482 1/20 0.38
CCNA1 P78396 1/20 0.38
AHCY P23526 1/20 0.38
CCNE2 O96020 1/20 0.34
HDAC1 Q13547 2/20 0.32
HDAC2 Q92769 2/20 0.32
HDAC8 Q9BY41 1/20 0.32
CDK5 Q00535 1/20 0.32
TMIGD3 P0DMS9 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21101589 0.93 CDK2 (0.38) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL24081983 0.90 CDK2 (0.40) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL24939857 0.88 AHCY (0.35) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL21101446 0.85 CDK2 (0.36) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL17460996 0.84 HSP90AA1 (0.41) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL24938834 0.83 CDK1 (0.47) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL21101808 0.82 CDK1 (0.34) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL21101442 0.81 CDK2 (0.47) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL24939854 0.81 CDK1 (0.33) CDK2CDK1CCNE1CCNB1PRKACA
SCHEMBL21102195 0.81 CDK1 (0.33) CDK2CDK1CCNE1CCNB1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230017958-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. (US) 2023-01-19 US disclosed
US-10946033-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Atea Pharmaceuticals, Inc. (US) 2021-03-16 US disclosed
US-20190201433-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. (US) 2019-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10946033-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment NSUN2, ADAR, NSUN3 CDK2 1258/4885CDK1 2298/4885CCNE1 3485/4885
US-20190201433-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT NSUN2, ADAR, NSUN3 CDK2 1333/4885CDK1 2349/4885CCNE1 3374/4885
US-20230017958-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT NSUN2, ADAR, NSUN3 CDK2 1333/4885CDK1 2349/4885CCNE1 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.